Navigation Links
University of Colorado Cancer Center earns major grant to develop new bladder cancer drugs
Date:8/15/2012

Bladder cancer kills by metastasizing usually to the lungs. A major grant from the National Cancer Institute will help the University of Colorado Cancer Center develop new drugs aimed at stopping bladder cancer's spread, which will kill an estimated 15,000 people in the United States this year.

"Strong preliminary work shows specific proteins that bladder cancer cells need in order to leave the bladder and attach to lung tissue. And additional work points to a number of drug candidates that block the activity of these proteins. The current project aims to select the best drug, use medicinal chemistry to boost its effectiveness, and move the optimized drug toward a human clinical trial," says Dan Theodorescu, MD, PhD, director of the University of Colorado Cancer Center, who will co-lead the project with David Ross, PhD, chair of the Department of Pharmaceutical Sciences at the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado.

The work is especially important in light of two current conditions: first, the extended absence of new drugs targeting bladder cancer, with the most recent advance being the addition of the drug gemcitabine, which earned FDA approval in 1997; and second, the recent explosion of technologies that allow the development of drugs that target a cancer's specific genetic abnormalities.

"We've seen a paradigm shift toward targeted therapies drugs that unlike the traditional chemotherapies selectively kill cancer cells while leaving healthy tissue unharmed. We hope to apply this paradigm to metastatic bladder cancer," says Colin Dinney, MD, co-principal investigator and chair of the Department of Urology at project partner MD Anderson.

"This project will target metastatic colonization in bladder cancer by targeting the proteins that drive these processes," says David McConkey, PhD, co-principal investigator at MD Anderson.

"We also hope to define the biomarkers of patients likely to respond to the drugs," Theodorescu says. Defining the population most likely to benefit from the new drugs would allow the group to select these patients for Phase I clinical trials the project's intended endpoint.

"We are all hopeful that three years from now, we'll have a drug in clinical trials that prevents or delays the development of metastatic disease high-risk patients following treatment of the primary tumor," Theodorescu says.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Hospital of the University of Pennsylvania selected to lead US nurse-training initiative
2. University of Pennsylvania and Novartis form alliance to expand use of personalized T cell cancer therapy
3. Boston University researchers expand synthetic biologys toolkit
4. Canadians super-sizing Canadas Food Guide servings: York University study
5. Tel Aviv University researcher says plants can see, smell, feel, and taste
6. Tel Aviv University research links childhood obesity to cancer risk
7. Marshall University scientist awarded NIH grant for lung cancer research
8. University of Texas Medical Branch to study hospital readmission
9. Oxford University Press acquires joint ownership of Journal of Surgical Case Reports
10. Tannins in sorghum and benefits focus of university, USDA study
11. ASHA grant funds cutting-edge AIDS research at Tel Aviv University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... 04, 2016 , ... Are You Concerned About Mold In Your Home or ... Air Quality Companies in VA, MD and DC, recently completed its application for the ... mold law in the district of Columbia is a good thing stated John Taylor, ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... on the perils of heroin that was watched live by 1 million viewers ... I. duPont-Columbia University Award. , ASU students at the Walter Cronkite School of ...
(Date:12/2/2016)... CO (PRWEB) , ... December 02, 2016 , ... Advanced ... announced it has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief ... for Advanced, Inc. , Jason brings extensive financial and operational leadership experience to ...
(Date:12/2/2016)... , ... December 02, 2016 , ... U.S. Surgeon General, ... with Mediaplanet, Dr. Murthy explains how he was inspired to practice medicine at an ... that medicine is about more than making diagnoses and prescribing medicine,” he states. “It ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... More than ... and while 84 percent of parents report speaking with their child about sex related ... sexually transmitted diseases. , Mediaplanet is proud to announce the launch of its second ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... WOONSOCKET, R.I. , Dec. 2, 2016 ... hold its annual Analyst Day in New York City on Thursday, December ... the CVS Health leadership team will provide an in-depth ... and enhance shareholder value. The company will also discuss ... audio and video webcast of the event will be ...
(Date:12/2/2016)... -- Orthopedic Implants (Including Spinal Implants, Reconstructive Joint ... a Significant Market Share Owing to a Large Global Baby ... ... According to a new report by Persistence Market Research ... Product Type Segment Projected to Witness a Significantly High CAGR ...
(Date:12/2/2016)... 2, 2016   CytoSorbents Corporation (NASDAQ: ... European Union approved CytoSorb ® cytokine adsorber to ... worldwide, announced that Dr. Phillip Chan , Chief ... LD Micro Main Event investor conference held from ... Luxe Sunset Boulevard Hotel in Los Angeles, ...
Breaking Medicine Technology: